These are preliminary reports that have not been peer-reviewed. They should not be regarded as conclusive, guide clinical practice/health-related behavior, or be reported in news media as established information. For more information, please see our FAQs.
SYNTHIA COVID Cernak Lab Paper 08-05-20.pdf (4.91 MB)

Reinforcing the Supply Chain of COVID-19 Therapeutics with Expert-Coded Retrosynthetic Software

submitted on 05.08.2020, 13:27 and posted on 07.08.2020, 10:24 by Yingfu Lin, Zirong Zhang, Babak Mahjour, Di Wang, Rui Zhang, Eunjae Shim, Andrew McGrath, Yuning Shen, Nadia Brugger, Rachel Turnbull, Shashi Jasty, Sarah Trice, Tim Cernak
Supply chains become stressed when demand for essential products increases rapidly in times of crisis. This year, the scourge of coronavirus highlighted the fragility of diverse supply chains, affecting the world’s pipeline of hand sanitizer, 1 toilet paper,2 and pharmaceutical starting materials. 3 Many drug repurposing studies are now underway. 4 If a winning therapeutic emerges, it is unlikely that the existing inventory of the medicine, or even the chemical raw materials needed to synthesize it,5 will be available in the quantities required to satisfy global demand. We show the use of a retrosynthetic artificial intelligence (AI) 6-10 to navigate multiple parallel synthetic sequences, and arrive at plausible alternate reagent supply chains for twelve investigational COVID-19 therapeutics. In many instances, the AI utilizes C–H functionalization logic, 11-13 and we have experimentally validated several syntheses, including a route to the antiviral umifenovir that requires functionalization of six C–H bonds. This general solution to chemical supply chain reinforcement will be useful during global disruptions, such as during a pandemic.


Email Address of Submitting Author


University of Michigan



ORCID For Submitting Author


Declaration of Conflict of Interest

The Regents of the University of Michigan have patented this work. This work was funded by MilliporeSigma.